ASCO GI 2023

Conference Coverage

ctDNA Testing in Colorectal Cancer Deemed Promising but Not Ready for Prime Time

Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.

Nonsurgical Approach Deemed Feasible for Patients With Early Rectal Cancer

A nonsurgical treatment strategy employing chemoradiotherapy is feasible for patients with early rectal cancer, a phase 3 trial suggests.

Adding Nab-Paclitaxel to Standard Care Does Not Improve Outcomes in Biliary Tract Cancers

Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.

Trifluridine Plus Tipiracil and Bevacizumab Deemed New Standard Care for Refractory Metastatic Colorectal Cancer

Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.

Benefit Seen With SBRT Before Sorafenib in Advanced HCC

SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.

ctDNA Monitoring Shows Promise for Anal Cancer Patients Receiving Chemoradiation

Monitoring of ctDNA may be useful for early response assessment in patients with anal cancer receiving chemoradiation, a study suggests.

Botensilimab Plus Balstilimab Yields Durable Responses in Refractory Metastatic Colorectal Cancer

Combination botensilimab and balstilimab elicits durable responses in refractory, metastatic, microsatellite-stable colorectal cancer, a phase 1 trial suggests.

NAPOLI-3 Results Support NALIRIFOX for Metastatic Pancreatic Cancer

NALIRIFOX outperformed treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer in the NAPOLI-3 trial.

Nanvuranlat Improves PFS in Heavily Pretreated, Advanced Biliary Tract Cancer

Nanvuranlat improved progression-free survival, compared with placebo, in heavily pretreated patients with advanced biliary tract cancer.

Combining TACE and Sorafenib Improves Survival in HCC With PVTT

The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.

Full Year of Adjuvant S-1 Chemo “Highly Recommended” for Stage II Gastric Cancer

Long-term results confirm that 4 courses of S-1 chemotherapy is inferior to the standard 8 courses in patients with stage II gastric cancer.

Procedural Volume May Impact Outcomes of Endoscopic Submucosal Dissection

Patients with gastric cancer or dysplasia who underwent endoscopic submucosal dissection at very low-volume centers had a higher risk of adverse outcomes.

Regorafenib May Be New Option for Advanced, Refractory Gastric/GEJ Cancer

Combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/GEJ cancer, a phase 3 study suggests.

Frontline Tislelizumab Improves Survival in PD-L1+, Advanced Gastric/GEJ cancer

Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.

HER-Vaxx Improves Survival in HER2+ Advanced Gastric/GEJ Cancer

Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.

Frontline Zolbetuximab Plus Chemo May Be New Standard Care for Gastric/GEJ Cancer

Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.

COVID-Related Delays in Gastrointestinal Cancer Diagnosis Did Not Impact Survival

The COVID-19 pandemic delayed the diagnosis of gastric, esophageal, or GEJ cancer but did not impact survival in a single-center study.